Dana Devine

Last updated
Dana Devine
Alma mater Boston University (BA, MA)
Duke University (PhD)
Awards Queen’s Golden Jubilee Award [1]
2015 Ortho Award, Canadian Society for Transfusion Medicine [2]
Scientific career
Fields Transfusion medicine
Institutions AABB
University of British Columbia
Canadian Blood Services

Dana Devine is a blood transfusion researcher and the president of AABB. [2] She was the editor-in-chief of Vox Sanguinis from 2012 to 2020. [3] Devine is also the Chief Scientist at Canadian Blood Services [2] and the director of the Centre for Blood Research at the University of British Columbia. [4] In 2015, she was elected as a fellow of the Canadian Academy of Health Sciences. [5] In 2022, she was elected as the President of the Biomedical Excellence for Safer Transfusion Collaborative. [6]

Contents

Education

Under the direction of Dr. Wendell F. Roose, Devine received her Ph.D. in immunology from Duke University in 1986. [7] [8] She previously completed a bachelor's degree in biology and a master's degree in marine biology, both at Boston University. [9]

Research and career

Devine first joined Canadian Blood Services (CBS) in 1999, following its creation as a result of the Krever Inquiry, as the executive director of research and development. [9] As director, she was instrumental in the development of the CBS’ accomplished Centre for Innovation, including its netCAD Blood4Research facility in Vancouver which is recognized globally for its work to drive innovation in transfusion medicine by collecting blood for research in blood collection, manufacturing, and storage. [10] [11] Other countries are taking inspiration from this model, including the U.S. and Australia. [10] She was vice-president of medical, scientific, and research affairs for 11 years before becoming Chief Scientist. [12] Her work at CBS has included improvements to testing for transfusion transmitted infection, donor and transplantation services, surveillance and epidemiology, and improvements to platelet unit manufacturing processes. [10] [12] Also in response to the Krever Inquiry, Devine co-founded the Centre for Blood Research in 2002. [13] In 2021, she became its director. [14]

Devine was elected president of AABB in 2020 and took office in October 2021. [2] [12] She was previously a vice-president of AABB. [15] An AABB member since 1998, Dana recognizes the challenges that the field is facing, including the maintenance of a stable and adequate blood supply, ensuring a sufficient and well-trained workforce, and advancing research. [16] As President, Devine has committed to being an advocate for research in this field, suggesting that the challenges being faced can be addressed through innovation. [16]

For her "critical scientific leadership to Canada’s blood system," Devine was elected a fellow of the Canadian Academy of Health Sciences in 2015. [5]

Devine has been a professor in the University of British Columbia's Department of Pathology and Laboratory Medicine since 2000, where she is also the Graduate Studies Program Director. [17]

Devine's research specialties are in blood system management and quality improvement, [2] platelet biology and coagulation, and complement biochemistry. [9] She is President of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, where her projects focus on improving the processing, quality, and utilization of conventional blood components. [6] [18] [19] She attended her first BEST meeting in 2002, subsequently joining the Conventional Components team under the direction of Dr. Sherrill Slitchter and Nancy Heddle. [6] Following this she co-led the team with Dr. Pieter van der Meer and still holds this role today. [6] Dana's efforts with BEST as an executive have led to the publishing of papers in notable journals. [6] As President, Devine is keen on leading Best Collaborative to address pressing issues in the community including the loss of DEHP from blood storage containers and reminding blood operators of the need to revalidate everything that they make. [6] As President, she will serve a four-year term for BEST Collaborative. [6]

Her laboratory at the University of British Columbia is focused on improving the storage quality of platelet units. [9] Devine is also involved in research on the use of convalescent plasma to treat COVID-19, [20] as well as research using Raman spectroscopy to assess the quality of stored red blood cells. [21] [22]

Dana also is a member of various boards for biotechnology companies and blood operators. Devine is the chair of the medical advisory board for Macopharma, a transfusion product company based in Lille, France. [6] She also serves as a member of the board of directors for a gene therapy start-up based in Boston, US, STMR.Bio. [23] She also sits on the research advisory boards for blood operators, including the Australian Red Cross Lifeblood, Vitalant, and the Bloodworks Northwest (formerly Puget Sound Blood Centre). [6] Dana Devine also chairs the medical advisory committee for the largest blood operator in the United States, the American Red Cross.

Dana has been credited with over one-hundred paper publications in scientific journals. [24] Her publications have garnered over ten-thousand citations. [25] Her most cited paper is title "Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions", with over 400 citations. [25]

Related Research Articles

<span class="mw-page-title-main">Blood transfusion</span> Intravenous transference of blood products

Blood transfusion is the process of transferring blood products into a person's circulation intravenously. Transfusions are used for various medical conditions to replace lost components of the blood. Early transfusions used whole blood, but modern medical practice commonly uses only components of the blood, such as red blood cells, white blood cells, plasma, platelets, and other clotting factors.

Transfusion medicine is the branch of medicine that encompasses all aspects of the transfusion of blood and blood components including aspects related to hemovigilance. It includes issues of blood donation, immunohematology and other laboratory testing for transfusion-transmitted diseases, management and monitoring of clinical transfusion practices, patient blood management, therapeutic apheresis, stem cell collections, cellular therapy, and coagulation. Laboratory management and understanding of state and federal regulations related to blood products are also a large part of the field.

<span class="mw-page-title-main">Platelet</span> Component of blood aiding in coagulation

Platelets or thrombocytes are a component of blood whose function is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot. Platelets have no cell nucleus; they are fragments of cytoplasm derived from the megakaryocytes of the bone marrow or lung, which then enter the circulation. Platelets are found only in mammals, whereas in other vertebrates, thrombocytes circulate as intact mononuclear cells.

A blood bank is a center where blood gathered as a result of blood donation is stored and preserved for later use in blood transfusion. The term "blood bank" typically refers to a department of a hospital usually within a Clinical Pathology laboratory where the storage of blood product occurs and where pre-transfusion and Blood compatibility testing is performed. However, it sometimes refers to a collection center, and some hospitals also perform collection. Blood banking includes tasks related to blood collection, processing, testing, separation, and storage.

<span class="mw-page-title-main">Blood donation</span> Blood withdrawal for use by another person via transfusion

A blood donation occurs when a person voluntarily has blood drawn and used for transfusions and/or made into biopharmaceutical medications by a process called fractionation. Donation may be of whole blood, or of specific components directly (apheresis). Blood banks often participate in the collection process as well as the procedures that follow it.

<span class="mw-page-title-main">AABB</span> Transfusion medicine and biotherapies association

AABB is an international, not-for-profit organization representing individuals and institutions involved in the field of transfusion medicine and biotherapies.

<span class="mw-page-title-main">Canadian Blood Services</span>

Canadian Blood Services is a non-profit charitable organization that is independent from the Canadian government. The Canadian Blood Services was established as Canada's blood authority in all provinces and territories except for Quebec in 1998. The federal, provincial and territorial governments created the Canadian Blood Services through a memorandum of understanding. Canadian Blood Services is funded mainly through the provincial and territorial governments.

<span class="mw-page-title-main">Royal Commission of Inquiry on the Blood System in Canada</span> Royal commission of inquiry into the tainted blood scandal in Canada

The tainted blood disaster, or the tainted blood scandal, was a Canadian public health crisis in the 1980s in which thousands of people were exposed to HIV and hepatitis C through contaminated blood products. It became apparent that inadequately-screened blood, often coming from high-risk populations, was entering the system through blood transfusions. It is now considered to be the largest single (preventable) public health disaster in the history of Canada.

<span class="mw-page-title-main">Transfusion-related acute lung injury</span> Medical condition

Transfusion-related acute lung injury (TRALI) is the serious complication of transfusion of blood products that is characterized by the rapid onset of excess fluid in the lungs. It can cause dangerous drops in the supply of oxygen to body tissues. Although changes in transfusion practices have reduced the incidence of TRALI, it was the leading cause of transfusion-related deaths in the United States from fiscal year 2008 through fiscal year 2012.

<span class="mw-page-title-main">Platelet transfusion</span> Treatment for bleeding irregularities

Platelet transfusion, also known as platelet concentrate, is used to prevent or treat bleeding in people with either a low platelet count or poor platelet function. Often this occurs in people receiving cancer chemotherapy. Preventive transfusion is often done in those with platelet levels of less than 10 x 109/L. In those who are bleeding transfusion is usually carried out at less than 50 x 109/L. Blood group matching (ABO, RhD) is typically recommended before platelets are given. Unmatched platelets, however, are often used due to the unavailability of matched platelets. They are given by injection into a vein.

<span class="mw-page-title-main">Héma-Québec</span>

Héma-Québec is a non-profit organization that supplies blood and other biological products of human origin to hospitals for the Canadian province of Quebec. The organization's headquarters is located in the Montreal borough of Saint-Laurent, Quebec, and it was created on March 26, 1998, as a successor to the Canadian Red Cross Blood Program and the Canadian Blood Agency on recommendation of the Krever Commission.

The International Society of Blood Transfusion (ISBT) is a scientific society founded in 1935 G.C, which promotes the study of blood transfusion and provides information about the ways in which blood transfusion medicine and science can best serve patients' interests. The society's central office is in Amsterdam, and there are around 1500 members in 103 countries. Currently, the President is Michael Busch.

<span class="mw-page-title-main">Health Sciences Authority</span> Statutory board under the Ministry of Health of the Singapore Government

The Health Sciences Authority (HSA) is a statutory board under the Ministry of Health of the Government of Singapore. It is a multi-disciplinary agency responsible for applying medical, pharmaceutical, and scientific expertise to protect and advance public health and safety.

A transfusion transmitted infection (TTI) is a virus, parasite, or other potential pathogen that can be transmitted in donated blood through a transfusion to a recipient. The term is usually limited to known pathogens, but also sometimes includes agents such as Simian foamy virus which are not known to cause disease.

Platelet transfusion refractoriness is the repeated failure to achieve the desired level of blood platelets in a patient following a platelet transfusion. The cause of refractoriness may be either immune or non-immune. Among immune-related refractoriness, antibodies against HLA antigens are the primary cause. Non-immune causes include splenomegaly, fever, and sepsis.

Patient Blood Management (PBM) is a set of medical practices designed to optimise the care of patients who might need a blood transfusion. Patient blood management programs use an organized framework to improve blood health, thus increasing patient safety and quality of life, reducing costs, and improving clinical outcomes. Some strategies to accomplish this include ensuring that anemia is treated prior to a surgical operation, using surgical techniques that limit blood loss, and returning blood lost during surgery to the patient via intraoperative blood salvage.

Mark Elliot Brecher is a physician specializing in pathology, in particular blood transfusion.

George William Gregory Bird was a British medical doctor, academic, researcher and haematologist known for his expertise in the fields of blood transfusion and immunohaematology. He founded the Department of Transfusion Medicine at the Armed Forces Medical College, Pune and was inducted into their Hall of Fame in 2010. A winner of the Karl Landsteiner Memorial Prize and Morten Grove Rasmussen Memorial Award of the American Association of Blood Banks, Gregory Bird was honoured by the Government of India in 1963, with the award of Padma Shri, the fourth highest Indian civilian award for his services to the nation.

Single unit transfusion refers to transfusing a single unit or bag of blood product to a person who is not bleeding and haemodynamically stable followed by an assessment to see if further transfusion is required.. The benefits of single unit transfusion include reduced exposure to blood products. Each unit transfused increases the associated risks of transfusion such as infection, transfusion associated circulatory overload and other side effects. Transfusion of a single unit also encourages less wastage of blood products and can be cost-effective. Single unit transfusion can be as part of an institutional or national guidelines and instituted with the help of a transfusion committee or transfusion practitioner. Education of medical staff is important and catch phrases such as "Why use two when one will do", "every ONE matters" or "one bag is best - then reassess" have been used.

<span class="mw-page-title-main">Marcel Bessis</span> French physician and scientist

Marcel Claude Bessis was a French physician known for research on blood cells.

References

  1. ↑ Lieutenant-Governor, Office of the Premier,Office of the (2003-01-15). "QUEEN'S GOLDEN JUBILEE MEDAL RECIPIENTS". archive.news.gov.bc.ca. Retrieved 2021-01-18.{{cite web}}: CS1 maint: multiple names: authors list (link)
  2. 1 2 3 4 5 "President-Elect". AABB . Retrieved 2021-01-18.
  3. ↑ "ISBT Annual Report 2019-2020" (PDF). International Society of Blood Transfusion . Archived (PDF) from the original on 2021-01-22.
  4. ↑ "Dr. Dana Devine takes the helm at the Centre for Blood Research | Life Sciences Institute". lsi.ubc.ca. Retrieved 2021-01-18.
  5. 1 2 "Congratulations & Welcome to our 2015 Fellows!" (PDF). Canadian Academy of Health Sciences . Archived (PDF) from the original on 2016-05-09.
  6. 1 2 3 4 5 6 7 8 9 "BEST Collaborative - 02 June 2022". www.bestcollaborative.org. Retrieved 2022-06-20.
  7. ↑ "Dana Devine (Director)". Centre for Blood Research. Retrieved 2021-01-18.
  8. ↑ McMaster, Robert (November 24, 2020). "Dr. Dana Devine appointment Director, Centre for Blood Research". UBC Faculty of Medicine. Archived from the original on 2021-01-22.
  9. 1 2 3 4 "Dana Devine". Pathology. Retrieved 2021-01-18.
  10. 1 2 3 "Dr. Dana Devine's schedule for CSPC 2018". cspc2018.sched.com. Retrieved 2022-06-20.
  11. ↑ "Dr. Dana Devine named president of AABB". www.blood.ca. Retrieved 2022-06-20.
  12. 1 2 3 Lewis, Catherine (January 19, 2021). "Chief scientist Dr. Dana Devine takes on directorship at Centre for Blood Research". www.blood.ca. Archived from the original on 2021-01-19. Retrieved 2021-01-19.
  13. ↑ "Joining forces to improve blood research in Canada". www.blood.ca. Retrieved 2021-01-18.
  14. ↑ "The CBR welcomes Dr. Dana Devine as Director". Centre for Blood Research. 2021-01-11. Retrieved 2021-01-18.
  15. ↑ "Dana Devine, American Association of Blood Banks: Profile and Biography". Bloomberg.com. Retrieved 2021-01-18.
  16. 1 2 "Dana Devine, PhD, Inaugurated as New AABB President". aabb.org. Retrieved 2022-06-20.
  17. ↑ "Dr. Dana Devine Accepts Graduate Studies Program Director Position". Centre for Blood Research. 2018-05-10. Retrieved 2021-01-18.
  18. ↑ "BEST Collaborative - Executive Team". www.bestcollaborative.org. Retrieved 2021-01-18.
  19. ↑ "BEST Collaborative - Conventional Components Team". www.bestcollaborative.org. Retrieved 2021-01-18.
  20. ↑ "Convalescent plasma used to treat COVID-19 faces hurdle after clinical trial results | CBC News". CBC News . October 23, 2020. Retrieved 2021-01-21.
  21. ↑ Henry Arnaud, Celia (April 12, 2019). "Raman techniques might one day allow blood banks to monitor the quality of their supplies". Chemical & Engineering News. Archived from the original on 2019-04-18. Retrieved 2021-01-18.
  22. ↑ "New way to check the quality of blood before opening the bag". www.blood.ca. Retrieved 2021-01-18.
  23. ↑ "Leadership". STRM.BIO. Retrieved 2022-06-20.
  24. ↑ "Dana V. Devine". ResearchGate. June 19, 2022. Retrieved June 19, 2022.
  25. 1 2 "Dana V Devine". scholar.google.ca. Retrieved 2022-06-20.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.